KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Total Non-Current Liabilities: 2019-2023

Historic Total Non-Current Liabilities for Esperion Therapeutics (ESPR) over the last 5 years, with Dec 2023 value amounting to $420.8 million.

  • Esperion Therapeutics' Total Non-Current Liabilities was N/A to $807.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $807.9 million, marking a year-over-year change of. This contributed to the annual value of $420.8 million for FY2023, which is 19.26% up from last year.
  • Esperion Therapeutics' Total Non-Current Liabilities amounted to $420.8 million in FY2023, which was up 19.26% from $352.9 million recorded in FY2022.
  • Esperion Therapeutics' 5-year Total Non-Current Liabilities high stood at $420.8 million for FY2023, and its period low was $67.2 million during FY2019.
  • In the last 3 years, Esperion Therapeutics' Total Non-Current Liabilities had a median value of $352.9 million in 2022 and averaged $368.8 million.
  • Data for Esperion Therapeutics' Total Non-Current Liabilities shows a peak YoY skyrocketed of 314.03% (in 2020) over the last 5 years.
  • Esperion Therapeutics' Total Non-Current Liabilities (Yearly) stood at $67.2 million in 2019, then spiked by 314.03% to $278.2 million in 2020, then grew by 19.63% to $332.8 million in 2021, then rose by 6.03% to $352.9 million in 2022, then rose by 19.26% to $420.8 million in 2023.